Who should get long-term anticoagulant therapy for venous thromboembolism and with what?

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):426-431. doi: 10.1182/asheducation-2018.1.426.

Abstract

After an initial 3 to 6 months of anticoagulation for venous thromboembolism (VTE), clinicians and patients face an important question: "Do we stop anticoagulants or continue them indefinitely?" The decision is easy in some scenarios (eg, stop in VTE provoked by major surgery). In most scenarios, which are faced on a day-to-day basis in routine practice, it is a challenging decision because of uncertainty in estimates in the long-term risks (principally major bleeding) and benefits (reducing recurrent VTE) and the tight trade-offs between them. Once the decision is made to continue, the next question to tackle is "Which anticoagulant?" Here again, it is a difficult decision because of the uncertainty with regard to estimates of efficacy and the safety of anticoagulant options and the tight trade-offs between choices. We conclude with the approach that we take in our clinical practice.

Publication types

  • Review

MeSH terms

  • Anticoagulants / therapeutic use*
  • Decision Making*
  • Humans
  • Time Factors
  • Venous Thromboembolism / drug therapy*

Substances

  • Anticoagulants